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background: The Fifth Evian Annual Reproduction (EVAR) Workshop Meeting discussed knowledge regarding contemporary genetics
in female reproduction.
methods: Specialist reproductive medicine clinicians and geneticists delivered presentations based on published literature and current
research. The content of this report is based on the expert presentations and subsequent group discussions that took place during this
Workshop.
results: Numerous ovarian genes with a role in infertility have been identiﬁed. Future challenges for genetic screening of patients, such as
those with polycystic ovary syndrome, primary ovarian insufﬁciency or endometriosis, include the identiﬁcation of high-throughput strategies
and how to apply these ﬁndings to infertile patients. The identiﬁcation of high-quality embryos in IVF using objective technologies remains a
high priority in order to facilitate single-embryo transfer. Gene expression proﬁling of cumulus cells surrounding the oocyte, and proteomic
and metabolomic approaches in embryo culture media may signiﬁcantly improve non-invasive embryo quality assessment.
conclusions: The way forward in advancing the knowledge of genes involved in reproduction was considered to be through genome-
wide association studies involving large numbers of patients. Establishing international collaboration is required to enable the application of
such technologies in sufﬁcient numbers of patients.
Key words: genes and female reproductive pathologies / embryo assessment / endometriosis / metabolomics / transcriptomics
* The Fifth Evian Annual Reproduction (EVAR) Workshop Meeting (16–17 April 2010) was organized to discuss contemporary genetic technologies and female reproduction. The content
of this manuscript is based on the presentations and discussions during this EVAR Workshop Meeting. The members of the group who authored this manuscript are: B.C.J.M. Fauser
(University Medical Center, Utrecht, the Netherlands), K. Diedrich (University Clinic of Schleswig-Holstein, Lu¨beck, Germany), P. Bouchard (Hoˆpital Saint Antoine and University
Pierre et Marie Curie, Paris, France), F. Domı´nguez (Embryomics, Derio, Spain), M. Matzuk (Baylor College of Medicine, Houston, USA), S. Franks (Institute of Reproductive & Develop-
mental Biology, Imperial College London, London, UK), S. Hamamah (ART/PGD Department, INSERM U 1040, Hoˆpital Arnaud de Villeneuve 34295 Montpellier, France), C. Simo´n (IVI,
Valencia University, Valencia, Spain), P. Devroey (Dutch-speaking Brussels Free University, Brussels, Belgium), D. Ezcurra (Merck Serono S.A., Geneva, Switzerland [an afﬁliate of Merck
KGaA, Darmstadt, Germany]), C.M. Howles (Merck Serono S.A., Geneva, Switzerland [an afﬁliate of Merck KGaA, Darmstadt, Germany]).
& The Author 2011. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
For Permissions, please email: journals.permissions@oup.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5) which
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Human Reproduction Update, Vol.17, No.6 pp. 829–847, 2011
Advanced Access publication on September 6, 2011 doi:10.1093/humupd/dmr033
Introduction
The study of genetics is a rapidly expanding ﬁeld in all areas of medi-
cine, including fertility. This review focuses on the genetic aspects of a
number of topics of importance in fertility medicine: ovarian function,
primary ovarian insufﬁciency (POI) and poor response to ovarian
stimulation, polycystic ovary syndrome (PCOS) and endometriosis.
In addition, new technologies for the assessment of oocyte and
embryo quality are reviewed, including gene expression proﬁling of
cumulus cells, proteomics and metabolomics.
The number of genes known to be expressed in the ovary and
involved in reproductive function has increased dramatically in
recent years. Increasing our understanding of the genes involved in
ovarian ageing and poor response to ovarian stimulation may lead
to improved clinical diagnosis and early detection, along with the
development of new agents or technologies for use in fertility treat-
ment. Although familial clustering of PCOS cases has been described,
the mode of inheritance remains uncertain. Candidate genes for
PCOS are discussed, although few studies have satisﬁed the rigorous
criteria of population selection and size, repeatability and correction
for multiple comparisons. Genetics also appear to have a role in
complex reproductive diseases, such as endometriosis. A number
of candidate gene families that may be differentially regulated in
endometriosis have been identiﬁed. New developments in this ﬁeld
include the identiﬁcation of a candidate population of endometrial
stem cells, the study of which may provide new insights into this
condition.
Improving our knowledge of the genetics of the ovary and the
genetic causes of infertility should lead to future improvements in fer-
tility treatment. For instance, it is now recognized that the oocyte is
not passive in the ovarian follicle but is a fundamental regulator of
somatic cell differentiation and function. The cumulus–oocyte
complex plays a central role in the regulation of folliculogenesis and
is important for the maturation, reprogramming and fertilization of
oocytes. Consequently, cumulus cell gene expression proﬁling is
being explored as a new method for the assessment of oocyte com-
petence and embryo developmental competence, which shows
promise for the near future.
Currently, IVF represents the only hope for many couples with fer-
tility problems. Embryo assessment has an enormous impact on the
success of IVF and, with moves towards single-embryo transfer
(SET), assessment of embryo quality is of the utmost importance.
Despite its evident importance, until recently, assessment of embryo
quality has depended on subjective morphological assessment
(Assou et al., 2011). Any objective method of embryo assessment
that could determine its potential for implantation, as well as its
health status, will increase success rates.
With the recent expansion of the current knowledge and develop-
ments in this area, a thorough review of contemporary genetics and
‘omics’ technologies in human reproduction is timely.
Methods
Prior to the Fifth Evian Annual Reproduction (EVAR) Workshop
Meeting, held on 16–17 April 2010, expert speakers prepared presen-
tations based on published literature and current research. Presenters
were asked to include comprehensive information using systematic
literature search criteria. Combinations of the following keywords
were used for PubMed searches: genes and fertility-associated pathol-
ogies, primary ovarian insufﬁciency, premature ovarian failure, genomics,
proteomics, metabolomics, endometriosis, polycystic ovary syndrome
(and PCOS), ﬂoating granulosa cell gene expression, cumulus cell gene
expression and protein expression proﬁling.
Following each presentation, a group discussion to reach joint con-
clusions on the topics covered was facilitated by the chairmen: Professors
Fauser and Diedrich. The content of this report is based on the expert
presentations and subsequent group discussions that took place during
the workshop meeting.
The discussions relating to each topic were complemented as necessary
with key publications that were known to the authors and electronic
literature searches. Articles of any type and published in English were
permitted and were unlimited by the date of publication.
Genetics of the ovary
Key genes involved in ovarian function
Our knowledge of the number of genes known to be involved in
ovarian function has increased dramatically in recent years.
Approaches to elucidate the role of speciﬁc genes involved in
human reproduction include the use of PCR, real-time PCR, ﬂuor-
escence in situ hybridization (FISH), single-nucleotide polymorphisms
(SNPs), array SNPs, comparative genomic hybridization (CGH),
array CGH (aCGH), genome-wide linkage analysis, candidate
gene-association studies, genome-wide association studies (GWAS)
and transgenic animal models. PCR and FISH have been available
for some time, but the more recent development of microarray tech-
nologies has increased substantially the volume of information avail-
able on the genetics of reproduction. Indeed, the online Ovarian
Kaleidoscope Database now contains information on more than
3100 ovarian-expressed genes and is a useful resource of knowledge
on ovarian genetics (http://ovary.stanford.edu).
Figure 1 shows a model of recognized genes involved in the
hypothalamo–pituitary–ovarian axis (Matzuk and Lamb, 2008).
Gene mutations shown to affect gonadotrophin synthesis or actions
and to cause infertility in humans have been summarized in a recent
review and are shown in Table I (Edson et al., 2009). Pre-antral follicu-
lar growth appears to be independent of gonadotrophins, but further
functional characterization of thecal cells (through antral, pre-
ovulatory, ovulation and corpus luteum phases) requires gonado-
trophin stimulation (Edson et al., 2009).
An important basic helix– loop–helix (HLH) transcription factor
that is essential for fertility, factor in the germline alpha (FIGLA),
was identiﬁed in 1997 (Liang et al., 1997). FIGLA is involved in for-
mation of the primordial follicle and knockout mice are infertile. In
FIGLA knockout mice ovaries, OCT4, a protein required for primor-
dial germ cell survival (Kehler et al., 2004), is absent (Joshi et al., 2007).
FIGLA is also involved in coordinating expression of the zona pellucida
(ZP) genes. Analysis of newborn ovaries has identiﬁed many oocyte-
speciﬁc genes that are down-regulated in FIGLA knockout mice
(Joshi et al., 2007). Thus, FIGLA acts as a central regulator of oocyte-
speciﬁc genes that play roles in folliculogenesis, fertilization and early
development.
Regulators of the development of primordial to primary follicles
include the following genes: newborn ovary homeobox (NOBOX), a
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homeobox-encoding gene (Suzumori et al., 2002; Rajkovic et al.,
2004), spermatogenesis- and oogenesis-speciﬁc basic HLH1
(SOHLH1) and 2 (SOHLH2) transcription factors (Pangas et al.,
2006; Hao et al., 2008; Toyoda et al., 2009) and Lim homeobox
protein 8 (LHX8) (Choi et al., 2008). All of these are expressed in
the late embryonic and newborn ovaries, and knockout models lack
primordial follicles and are sterile.
SOHLH1 disruption has been shown to down-regulate the
expression of FIGLA and NOBOX genes and their targets: ZP1,
ZP2, ZP3 and OCT4, growth differentiation factor 9 (GDF9) and
LHX8 (Pangas et al., 2006) and up-regulate the expression of stimu-
lated by retinoic acid gene 8 (STRA8), which is directly or indirectly
repressed by NOBOX and LHX8 (Choi et al., 2008). SOHLH1 and
SOHLH2 appear to be master–master regulators of other master
transcription factors. The presence of two master–master regula-
tors (SOHLH1 and SOHLH2) supports the concept that it is
important to have more than one transcription factor regulating
key genes (Toyoda et al., 2009). A summary of these ﬁndings is
shown in Fig. 2.
The transforming growth factor b superfamily, which includes GDF9
and bone morphogenetic protein 15 (BMP15), is the largest family of
growth factor ligands in mammals. They function in multiple develop-
mental and physiological processes (Chang et al., 2002).
Oocyte-expressed GDF9 is essential for granulosa cell proliferation
and differentiation at the one- to two-layer follicle transition (Dong
et al., 1996). A key role of GDF9 at this transition is to suppress
inhibin-a and a secondary role is to stimulate the formation of a ster-
oidogenically functional theca (Elvin et al., 1999a, b). The GDF9 pro-
moter contains three NOBOX-binding elements (Choi and Rajkovic,
2006).
Novel oocyte-enriched gene, G-protein receptor 149
G-protein receptor 149 (GPR149) is a recently identiﬁed ‘antifertility’
gene, expressed in ovaries and oocytes, which is of particular interest.
It was identiﬁed from searches of online databases for genes with
expression patterns similar to GDF9. These genes were grouped by
gene ontology into G protein-coupled receptors, three of which
were identiﬁed as being of potential importance: GPR3, GPR149 and
GPR175 (Mehlmann et al., 2004; Aki et al., 2008; Edson et al., 2010).
Unique features of the GPR149 receptor include a very long
carboxy-terminal tail of 360 amino acids. Phylogenetic analysis of
GPR149 suggests that it is widely conserved in vertebrates (Edson
et al., 2010). GPR149-deﬁcient mice have been generated and found
to be viable and fertile (Edson et al., 2010). GPR149-null females
have increased fertility (large litter sizes, high litter frequency and pro-
longed time in oestrus). Increased fertility was secondary to ovulation,
which was likely due to reduced follicular atresia and a corresponding
increase in the number of antral follicles. Importantly, the number of
antral follicles was not depleted in mature GPR149-null female mice,
which suggests that the ovaries of GPR149-null females do not
undergo premature ageing (Edson et al., 2010).
Expression of the follicle-stimulating hormone receptor gene (FSHR)
and GDF9 is increased in GPR149-deﬁcient mice. Elevated levels of
FSHR increase cyclin D2 levels in granulosa cells and stimulate cell pro-
liferation (Edson et al., 2010). If GPR149 is found to have a similar func-
tion in humans, GPR149 antagonists may represent potential new
fertility treatments.
Cumulus expansion
Cumulus cells are specialized cells that surround and nourish the
oocyte. They have important roles in promoting cytoplasmic
Figure 1 Model of ovarian genes recognized in 2008. Reproduced with permission from Macmillan Publishers Ltd (Matzuk and Lamb, 2008).
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maturation of oocytes, which is necessary for pronuclear formation
and subsequent developmental capability (Vanderhyden and Arm-
strong, 1989). Cumulus expansion involves production of a hyaluronic
acid-rich extracellular matrix that surrounds the oocyte. In the peri-
ovulatory period, this expansion has several important roles including
protection of the oocyte, aiding growth of the cumulus–oocyte
complex, permitting oocyte capture by oviductrial ﬁmbria and
enhancement of the fertilization ability of sperm.
The genes involved in the process of cumulus expansion include
GDF9 and BMP15 with involvement of hyaluronan synthase 2
(HAS2), tumour necrosis factor-induced protein-6 (TNFIP6),
pentraxin 3 (PTX3), prostaglandin-endoperoxide synthase 2
(PTGS2) and gremlin 1 (GREM1) (Elvin et al., 1999b, 2000; Varani
et al., 2002; Pangas et al., 2004). The expression of these genes pro-
duces factors involved in the production of granulosa cells, pro-
motion of glycolysis, stimulation of sterol biosynthesis and amino
acid transport with bidirectional communication between the
oocyte and cumulus cells (Dong et al., 1996; Elvin et al., 1999a,
2000; Yan et al., 2001; Varani et al., 2002; Pangas et al., 2004).
When the cumulus cells are removed (e.g. during ICSI procedures),
supplying the oocyte with these substances may have beneﬁt.
Therefore, cumulus cells could potentially be used in IVF
.............................................................................................................................................................................................
Table I Gene mutations affecting gonadotrophin synthesis or actions and causing infertility.
Gene Phenotype OMIM gene
[OMIM infertility]
Bone morphogenetic protein 15 (BMP15) Hypergonadotrophic ovarian failure (POF4) 300247 [300510]
Bone morphogenetic protein receptor 1B
(BMPR1B)
Ovarian dysfunction, hypergonadotrophic hypogonadism and acromesomelic
chondrodysplasia
603248
Chromobox homolog 2, Drosophila
polycomb class (CBX2; M33)
Autosomal 46,XY, male-to-female sex reversal (phenotypically perfect females) 602770 (67)
Chromodomain helicase DNA-binding
protein 7 (CHD7)
CHARGE syndrome and Kallmann syndrome (KAL5) 608892 [612370]
Diaphanous homolog 2 (DIAPH2) Hypergonadotrophic, premature ovarian failure (POF2A) 300108 [300511]
Fibroblast growth factor 8 (FGF8) Normosmic hypogonadotrophic hypogonadism and Kallmann syndrome (KAL6) 600483 [612702]
Fibroblast growth factor receptor 1
(FGFR1)
Kallmann syndrome (KAL2) 136350 [147950]
FSH receptor (FSHR) Hypergonadotrophic hypogonadism and ovarian hyperstimulation syndrome 136435
FSHb (FSHB) Deﬁciency of follicle-stimulating hormone, primary amenorrhoea and infertility 136530 [229070]
Forkhead box L2 (FOXL2) Isolated premature ovarian failure (POF3) associated with BPES type I; FOXL2
402C G mutations associated with human granulosa cell tumours
605597 [608996]
Fragile X mental retardation 1 (FMR1) Premature ovarian failure (POF1) associated with premutations 309550 [311360]
GnRH receptor (GNRHR) Hypogonadotrophic hypogonadism 138850
GnRH (GNRH1) Normosmic hypogonadotrophic hypogonadism 152760 (769, 770)
Kallmann syndrome 1 (KAL1) Hypogonadotrophic hypogonadism and insomnia, X-linked Kallmann syndrome (KAL1) 308700
KISS1 receptor (KISS1R; GPR54) Hypogonadotrophic hypogonadism 604161
LHb (LHB) LHB G102S mutations associated with infertility 152780
LH/choriogonadotrophin receptor
(LHCGR)
Hypergonadotrophic hypogonadism (luteinizing hormone resistance) 152790
Nuclear receptor subfamily 0, group B,
member 1 (NROB1; DAX1)
X-linked congenital adrenal hypoplasia with hypogonadotrophic hypogonadism;
dosage-sensitive male-to-female sex reversal
300473 [300200;
300018]
Nuclear receptor subfamily 5, group A,
member 1 (NR5A1; SF1)
46,XY male-to-female sex reversal and streak gonads and congenital lipoid adrenal
hyperplasia; 46,XX gonadal dysgenesis and 46,XX primary ovarian insufﬁciency
184757 (771)
Premature ovarian failure 1B (POF1B) Hypergonadotrophic, primary amenorrhea (POF2B) 300603 [300604]
Prokineticin (PROK2) Normosmic hypogonadotrophic hypogonadism and Kallmann syndrome (KAL4) 607002 [610628]
Prokineticin receptor 2 (PROKR2) Kallmann syndrome (KAL3) 607123 [244200]
R-spondin family, member 1 (RSPO1) 46,XX, female-to-male sex reversal (individuals contain testes) 609595
Sex-determining region Y (SRY) Mutations lead to 46,XY females; translocations lead to 46,XX males 480000
SRY-related HMB-box gene 9 (SOX9) Autosomal 46,XY male-to-female sex reversal (campomelic dysplasia) 608160
Tachykinin 3 (TAC3) Normosmic hypogonadotrophic hypogonadism 162330
Tachykinin receptor 3 (TACR3) Normosmic hypogonadotrophic hypogonadism 162332
Reproduced with permission from the Endocrine Society (Edson et al., 2009). Because of space limitations, most cases associated with female-to-male sex reversal due to
steroidogenesis defects, syndromes and chromosomal abnormalities are excluded from the table. The primary reference (in parentheses) is included for work not yet described in
OMIM.
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programmes in co-culture with embryos to support development to
the blastocyst stage.
Cumulus cell gene expression proﬁling has been used recently as a
method of assessing oocyte quality and embryo development and is
discussed later in this review.
POI and poor response to ovarian stimulation
POI, which was known previously as premature ovarian failure, and fol-
licular atresia may share several common mechanisms, including abnor-
mal apoptosis, an abnormal number of primordial follicles and/or
abnormal follicular maturation. Ovarian failure, whether natural or
induced as a consequence of pathological insults, is driven by depletion
of ovarian follicles through apoptosis (Tilly, 2001; De Vos et al., 2010).
The mean age at which the menopause occurs is 51 years and, with
a range between 40 and 60 years, is relatively wide-ranging (Broek-
mans et al., 2009). Hence, exhaustion of the primordial follicle pool
in some women takes 50% more time compared with others. Evi-
dence suggests that all women are born with a similar number of fol-
licles (Gosden and Faddy, 1994) and this number steadily dwindles
throughout life as a result of atresia and recruitment towards ovulation
(Gosden and Faddy, 1998). The rate of depletion of the follicular pool
determines the age at which the menopause occurs and is thought to
be controlled by multiple genes. Although only 1–2% of women
undergo premature menopause, deﬁned as before 40 years of age,
studies in this population may provide important information regarding
the genes involved in ovarian ageing and may help to predict better the
age of menopause for individual patients (Torgerson et al., 1997;
Goswami and Conway, 2005). Both infertility and poor response to
ovarian hyperstimulation have been associated with subsequent
early menopause in several studies (Farhi et al., 1997; Nikolaou
et al., 2002; de Boer et al., 2003; Lawson et al., 2003; Broekmans
et al., 2009). Poor response to ovarian hyperstimulation is generally
taken to be the retrieval of fewer than ﬁve oocytes and is associated
with lower than average pregnancy rates (van der Gaast et al., 2006;
Verberg et al., 2009).
The mean age of menopause is remarkably similar throughout the
world and does not appear to have changed over time (Torgerson
et al., 1997). There appears to be a strong link between mothers’
and daughters’ menopausal ages (Torgerson et al., 1997; van Asselt
et al., 2004; Murabito et al., 2005) and twin studies suggest that the
age of natural menopause is genetically linked (Snieder et al., 1998;
Treloar et al., 1998). Other factors, including smoking and alcohol
consumption, body mass index and parity, appear to play a minor role.
Aside from loss of fertility, POI underlies the emergence of an array
of health problems in ageing women, including increased risks of car-
diovascular disease and osteoporosis (Hartge, 2009; De Vos et al.,
2010). In women who undergo bilateral oophorectomy before the
natural menopause, with subsequent early reduction in oestrogen
levels, evidence suggests an increased risk of cognitive impairment
and neurological disorders such as Parkinson’s disease (Rocca et al.,
2007, 2008).
Known causes of POI
In 70–90% of cases, the cause of POI in humans is unknown. Known
causes include bilateral oophorectomy, chemotherapy, radiotherapy
and Turner syndrome (TS; 45 X). Other known causes of POI
include autoimmune disease [including autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy due to rare mutations in the AIRE
(autoimmune regulator) gene (Ahonen et al., 1990)], pseudohypopar-
athyroidism, congenital disorders of glycosylation, galactosaemia,
infections (e.g. herpes zoster and cytomegalovirus), syndromes [such
as Fragile X (FMR1 gene) (Murray et al., 1999) and blepharophimosis-
ptosis-epicanthus inversus (BPES)] and isolated gene defects (Uda
Figure 2 Working model of the regulation of oocyte gene expression. As described in the text, a complex of SOHLH1/2 is believed to be a master–
master regulator of other master transcription factors (boxed or circled). Key downstream transcriptional targets (GDF9, OCT4 and ZP1–3) are also
shown.
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et al., 2004). Known isolated gene defects involved in POI are listed in
Table II (Miller and Chatten, 1967; Ahonen et al., 1990; Leslie et al.,
1992; Aittomaki et al., 1995; Bione et al., 1998; Chun et al., 1999;
Murray et al., 1999; Takahashi et al., 1999; Prueitt et al., 2000,
2002; Crisponi et al., 2001; Di Pasquale et al., 2004; Dixit et al.,
2004, 2005, 2006; Fogli et al., 2004; Luoma et al., 2004; Sato et al.,
2004; Tung et al., 2006; Watkins et al., 2006; Laissue et al., 2007;
Qin et al., 2007; Kovanci et al., 2008; Mandon-Pepin et al., 2008;
Vinci et al., 2008; Zhao et al., 2008; Lourenco et al., 2009; van
Dooren et al., 2009; Chrzanowska et al., 2010; De Vos et al., 2010).
POI has been linked with several X chromosome-linked defects.
Most women with TS have primary amenorrhoea, but some are
fertile. Factors with a positive predictive value for fertility include
mosaicism, normal FSH and anti-Mu¨llerian hormone levels, and
spontaneous menarche and puberty (Borgstrom et al., 2009).
BMP15 has been described as the ﬁrst gene on the X chromosome
with a role in ovarian function (Layman, 2006). As discussed earlier,
together with GDF9, BMP15 plays an important role in oocyte–
cumulus cell signalling (Layman, 2006; Gilchrist et al., 2008) and it
has been suggested that GDF9 and BMP15 mutations are involved in
POI (Laissue et al., 2006). A naturally occurring BMP15 mutation in
ewes causes increased ovulation rates, and twin and triplet births in
heterozygotes, but primary ovarian failure in homozygotes (Galloway
et al., 2000). In humans, a natural heterozygous mutation in the pro-
peptide region of the BMP15 gene has been associated with hypergo-
nadotrophic ovarian failure due to ovarian dysgenesis (Di Pasquale
et al., 2004). The mutation appeared to be associated with reduced
granulosa cell growth. This suggests that BMP15 is required for
.............................................................................................................................................................................................
Table II Human genes associated with ovarian insufﬁciency/failure.
Acronym Name
AIRE (Ahonen et al., 1990) Autoimmune regulator
ATM (Miller and Chatten, 1967) Ataxia telangiectasia mutated
BHLHB9 (De Vos et al., 2010) Basic helix– loop–helix domain-containing, class B, 9
BMP15 (Di Pasquale et al., 2004) Bone morphogenetic protein
DACH2 (Prueitt et al., 2002) Drosophila dachsund
DIAPH2 (Bione et al., 1998) Homologue Drosophila diaph
FMR1 (Murray et al., 1999) Fragile X mental retardation 1
FMR2 (Murray et al., 1999) Fragile X mental retardation 2
XIST (Sato et al., 2004) X inactivation transcript
XPNPEP2 (Prueitt et al., 2000) Propyl aminopeptidase
DAZL (Tung et al., 2006) Deleted azoospermia
DCM1 (Mandon-Pepin et al., 2008) Disrupted meiotic cDNA 1
EIF2B (Fogli et al., 2004) Eukaryotic translation initiation
ESR1 (Tung et al., 2006) Oestrogen receptor
FIGLA (Zhao et al., 2008) Murine factor germline alpha
FOXL2 (Crisponi et al., 2001) Forkhead transcription factor
FOXO1A (Watkins et al., 2006) Forkhead box 01A
FOXO3a (Vinci et al., 2008) Forkhead box O3a
FSHR (Aittomaki et al., 1995) FSH receptor
GALT (Leslie et al., 1992) Galactose phosphate transferase
GDF9 (Dixit et al., 2005) Growth differentiation factor 9
GPR3 (Kovanci et al., 2008) G protein-coupled receptor
INHA (Dixit et al., 2004) Inhibin A
LHB (Takahashi et al., 1999) LH beta
MSH5 (Mandon-Pepin et al., 2008) MutS homolog 5
NOBOX (Qin et al., 2007) Murine newborn ovary box
NOGGIN (Laissue et al., 2007) Binds and inactivates members of the transforming growth factor-b superfamily signalling proteins
NR5A1 (SF-1) (Lourenco et al., 2009) Nuclear receptor subfamily 5 A1
NSB1 (Chrzanowska et al., 2010) Nijmegen breakage syndrome 1
PGRMC1 (van Dooren et al., 2009) Progesterone receptor membrane component-1
POLG (Luoma et al., 2004) Mitochondrial DNA polymerase gamma mutations
TGFBR3 (Dixit et al., 2006) Tumour growth factor receptor
WT1 (Chun et al., 1999) Wilms Tumor 1
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human folliculogenesis. However, further studies are needed to eluci-
date the role of BMP15 in humans.
Fragile X syndrome is caused by mutations of the FMR1 gene in the
distal part of the long-arm of the X chromosome. This occurs rela-
tively frequently and is the most common cause of mental retardation,
behavioural difﬁculties, autism and learning difﬁculties in boys. The syn-
drome is caused by an abnormal number of CGG repeats in the
5′-untranslated region of the gene. Typically, the number of repeats
is fewer than 45, while abnormal genes may have more than 200,
which causes FMR1 gene inactivation. Women who have between
55 and 200 repeats (1 in 590 women) carry a premutation that
causes altered ovarian function and POI (Wittenberger et al., 2007).
Some studies have suggested, however, that there is no linear corre-
lation between the number of repeats and POI, with the highest risk
between 80 and 100 repeats (Sullivan et al., 2005; Ennis et al.,
2006). Up to 28% of Fragile X premutation carriers (45–200
repeats) develop POI (Welt et al., 2004). Such women appear to
have normal menstrual cycles, with slightly raised FSH levels (Welt
et al., 2004).
FOXL2 is involved in the development of granulosa cells and, in
addition to female infertility, FOXL2 mutations have been shown to
cause eyelid/forehead dysmorphology (BPES) (Uda et al., 2004). Fur-
thermore, studies have suggested that in a small proportion of patients
with BPES, the genetic defect does not reside within the coding region
of the FOXL2 gene (De Baere et al., 2001) and incidences of POI with
FOXL2 mutations in patients without BPES have also been reported
(De Baere et al., 2001; Harris et al., 2002).
Mutations in the NR5A1 [FSH or steroidal factor 1 (SF-1)] gene, a
key transcriptional regulator of genes involved in the hypothalamic–
pituitary–steroidogenic axis, have also been associated with impair-
ment of ovarian development and function (Lourenco et al., 2009).
Such mutations are associated with POI and also with disorders of
sex development in men. NR5A1 is expressed in multiple cell types
in the foetal, post-natal, prepubertal and mature ovary, in the adult
adrenal cortex and in the Sertoli and Leydig cells of the testis
(Lavorgna et al., 1991; Luo et al., 1994; Jeyasuria et al., 2004). The
protein regulates the transcription of key genes involved in sexual
development and reproduction, including STAR (encoding steroidogenic
acute regulatory protein), CYP17A1 (encoding 17-alphahydroxylase),
CYP11A1 (encoding cytochrome P-450 cholesterol side-chain cleavage),
LHB (encoding the beta subunit of LH), AMH (encoding anti-Mu¨llerian
hormone), CYP19A1 (encoding aromatase) and INHA (encoding
inhibin-a subunit) (Shen et al., 1994; Keri and Nilson, 1996; Sugawara
et al., 1997; Hanley et al., 2001; Gurates et al., 2003; Weck and Mayo,
2006; Mendelson and Kamat, 2007).
Women with FSHR-inactivating mutations develop multiple follicles
in the early primordial, primary, secondary and pre-antral stages, but
no antral or pre-ovulatory follicles (as their development is
FSH-dependent) and such mutations are rare causes of POI (Aitto-
maki et al., 1995; Doherty et al., 2002). LH receptor mutations
have also been associated with infertility. In a study of three sisters
with an LH receptor mutation (two homozygous, one heterozygous),
both homozygous women had normal menarche and regular men-
strual cycles initially, but then experienced early oligomenorrhoea.
The homozygous sisters underwent fertility treatment, which was
unsuccessful in both cases. The heterozygous sister, however, had
ﬁve natural pregnancies with two live births (Bruysters et al., 2008).
Other candidate genes
Three types of study have been used to investigate the genetics of the
natural menopause in humans; genome-wide linkage analysis, candi-
date gene-association studies and GWAS. Although GWAS have
been used in many disease areas, until recently they had not been per-
formed in reproductive medicine. Such studies need large numbers of
patients and are expensive to perform, but can provide major break-
throughs in our understanding of disease aetiology.
Candidate genes for premature menopause include those involved
in steroidogenesis, estradiol signalling and the cardiovascular system.
A recent systematic review summarizes candidate genes and SNPs
in association with the natural age at menopause and identiﬁed two
genomic regions (19q13.42 and 20p12.3), containing two promising
candidate genes [BR serine threonine kinase 1 gene (BRKS1) and main-
tenance complex component (MCM)] (Voorhuis et al., 2010).
Genome-wide linkage analysis studies have suggested the involve-
ment of B-cell lymphoma 2 (BCL2) and gonadotrophin-releasing
hormone 1 (GnRH1) as genes with suggestive linkage with the
natural age of menopause (van Asselt et al., 2004; Murabito et al.,
2005). The ﬁrst genome-wide linkage search in familial POI identiﬁed
a region on chromosome 5q14.1–q15 that may harbour a novel POI
susceptibility gene (Oldenburg et al., 2008), and a recent GWAS
identiﬁed ADAMTS19 (5q31) as a possible candidate gene for POI
(Knauff et al., 2009).
Other strategies to discover and study new candidate genes include
the use of animal models. Inactivation of the proapoptotic BAX gene in
mice has been shown to prolong ovarian function into advanced age
(Perez et al., 2007) with minimization of many age-related health pro-
blems and, importantly, no increase in tumour incidence. Further
studies are needed, however, to assess the importance of the BAX
gene on ovarian function in humans.
aCGH analysis is able to detect submicroscopic chromosomal
rearrangements with a high genomic resolution. This technique was
used in a large cohort of Caucasian women with POI and identiﬁed
eight copy number variations in eight different genes associated with
POI. Five of these genes [DNAH5 (dynein axonemal heavy chain),
NAIP (neuronal apoptosis inhibitory protein), DUSP22 (dual speciﬁcity
phosphatases), AKT1 (akt murine thymoma viral oncogene homolog 1)
and NUPR1 (nuclear protein 1)] are involved in reproduction; two are
involved in reproductive diseases (DNAH5 and NAIP), two in repro-
ductive endocrinology (DUSP22 and NUPR1) and one in folliculogen-
esis (AKT1). Thus, these genes represent potential candidate genes
in POI (Aboura et al., 2009), but the results need to be conﬁrmed
in other studies.
Recently, four SNPs on chromosomes 19, 20, 6 and 5 have been
associated with normal variation in menopausal age. They were ident-
iﬁed through two GWAS and had a signiﬁcant impact on the odds of
having an early menopause in an independent cohort of women from
the Breakthrough Generations Study. Thus, these genetic variants,
which are associated with normal variation in menopausal age, are
also signiﬁcant risk factors for early menopause (Murray et al., 2011).
Investigating POI
In the clinical setting, causative genes of POI are identiﬁed in very few
cases. However, some syndromic causes of POI have physical manifes-
tations that can provide clues to its aetiology; e.g. eyelid abnormalities
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of patients with BPES and short stature in TS (Uda et al., 2004;
Borgstrom et al., 2009). A family history of learning difﬁculties in
boys suggests the presence of Fragile X syndrome and the presence
of autoimmune disorders may suggest an immunological aetiology
(Ahonen et al., 1990; Murray et al., 1999). When investigating POI,
after obtaining informed consent, it is important to perform karyotyp-
ing and to screen for FMR1 and NR5A1 mutations as both have serious
familial implications.
Polycystic ovary syndrome
Genetic factors in the aetiology of PCOS
PCOS is a complex, heterogeneous disorder of uncertain aetiology.
Studies in animal models of PCOS, notably in the Rhesus monkey,
have given rise to the hypothesis that PCOS has its origin in foetal
life (Abbott et al., 2002). In human females, exposure to excess andro-
gen, at any stage from foetal development of the ovary to the onset of
puberty, leads to many of the characteristic features of PCOS, includ-
ing abnormalities of LH secretion and insulin resistance (Abbott et al.,
2002; Xita and Tsatsoulis, 2006). In human post-natal life, the natural
history of PCOS can be further modiﬁed by factors affecting insulin
secretion and/or action, most importantly, nutrition (Ciampelli
et al., 1999). There is strong evidence that genetic factors play an
important part in the aetiology of PCOS (Franks and McCarthy,
2004; Franks et al., 2006; Urbanek, 2007). The familial clustering of
cases (Cooper et al., 1968; Ferriman and Purdie, 1979; Givens,
1988; Hague et al., 1988; Lunde et al., 1989; Carey et al., 1993),
greater concordance in monozygotic compared with heterozygotic
twins (Vink et al., 2006) and heritability of endocrine and metabolic
features of PCOS (Legro et al., 1998, 2002; Franks et al., 2008) all
provide support for the involvement of genetic factors.
Genetic studies in PCOS
In the search for genes involved in the aetiology of PCOS, the focus
has been on genes implicated in folliculogenesis, such as follistatin,
genes involved in the androgen biosynthetic pathway (such as
CYP11A, CYP17 and CYP19) and those affecting insulin secretion or
action [such as transcription factor 7-like 2 (TCF7L2), potassium
inwardly rectifying channel, subfamily J, member 11 (KCNJ11),
insulin receptor and peroxisome proliferator-activated receptor-g
(PPAR-g)] (Franks and McCarthy, 2004; Gaasenbeek et al., 2004;
Escobar-Morreale et al., 2005; Christopoulos et al., 2008).
However, despite the evaluation of more than 70 genes, the candidate
gene approach has, to date, proved disappointing. Due to limited
sample sizes, and genetic and phenotypic heterogeneity, ﬁndings
have often been ambiguous or not reproducible. Even the few
studies that have been sufﬁciently well powered to either identify or
exclude candidate susceptibility loci have produced limited positive
ﬁndings.
Two notable exceptions, for which there is convincing evidence for
a role in PCOS, are the ﬁbrillin-3 gene (FBN3) and the fat-mass and
obesity-associated (FTO) gene loci. Evidence for linkage disequilibrium
was observed at D19S884, a dinucleotide repeat marker on chromo-
some 19p13.2 (Urbanek et al., 1999, 2005; Tucci et al., 2001). Geno-
typing of the region around D19S884 subsequently identiﬁed FBN3 as
a likely candidate for a PCOS susceptibility gene.
The association of the FTO locus (on chromosome 16) with type 2
diabetes and obesity (Frayling et al., 2007) led researchers to explore a
role for this gene in the aetiology of PCOS. In a case–control study, an
association was found between PCOS status and FTO genotype
(Barber et al., 2008). FTO variants that were known to predispose
to obesity were also implicated in altered susceptibility to PCOS, con-
ﬁrming the mechanistic link between these conditions. FTO variants
have also been shown to strongly inﬂuence the glucose intolerance
component of the metabolic syndrome in patients with PCOS
(Attaoua et al., 2008). Based on the results from various studies of
FTO in PCOS, the consensus is that the association is predominantly
with obesity in women with PCOS, rather than PCOS per se
(Barber et al., 2008; Tan et al., 2010; Wehr et al., 2010).
Blastocysts derived from women with PCOS have markedly differ-
ent transcriptome proﬁles than blastocysts from normal controls
(Katz-Jaffe et al., 2010); proteomic proﬁling identiﬁed 12 biomarkers
that displayed signiﬁcantly decreased expression in PCOS. It was pos-
tulated that these differences may, in part, explain the reduction in
reproductive capacity of women with PCOS.
Recently, the role of microRNAs (miRNAs) has been studied in the
pathogenesis of endometriosis and associated reproductive conditions
[for review, see Ohlsson Teague et al. (2010)]. miRNAs are short
(about 21 nucleotides), single-stranded RNAs that regulate gene
expression at the post-transcriptional level (non-coding). Differences
in miRNA proﬁles in transferable blastocysts from women with
PCOS compared with those from donor fertile controls have been
shown (McCallie et al., 2010).
Although the search for candidate genes is bound to continue, it
seems increasingly likely that GWAS (of the kind that has paid divi-
dends in the search for genes in type 2 diabetes) is the approach
that is most likely to uncover the genes contributing to PCOS.
Although this would require substantial resources and very large
case–control populations, the limitations of earlier studies may be
overcome and new studies promise to be more informative. Indeed,
results have been published recently of a GWAS in Han Chinese
women with PCOS. A number of loci of interest were identiﬁed,
including one close to the gene encoding the LH receptor (Chen
et al., 2011).
Genetics of disorders of the
female reproductive system
Endometriosis
Endometriosis is an oestrogen-dependent condition that is character-
ized by the presence of endometrium-like tissue at ectopic sites such
as the pelvic peritoneum and ovaries (Fig. 3). Pelvic pain and infertility
are the most common features of endometriosis. There are several
proposed hypotheses to explain the pathogenesis of endometriosis
(Sasson and Taylor, 2008); the most widely accepted theory is that
of retrograde menstruation. The mechanisms involved in the develop-
ment of an endometriotic lesion in the pelvic peritoneum may include
attachment, invasion into the mesothelium, and survival and prolifer-
ation of ectopic endometrial cells.
The basic underlying cause of endometriosis is likely to be multifac-
torial and involves interplay between several factors. The pathogenesis
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of endometriosis may, for example, involve retrograde menstruation in
the context of an abnormal immune response and a genetic predispo-
sition to developing endometriotic lesions; this may possibly occur
after exposure to an unidentiﬁed environmental factor (Sasson and
Taylor, 2008).
The study of endometriosis is complicated by a number of factors:
these include the presence of different cell types within endometriotic
lesions and the involvement of different pathogenic mechanisms in the
formation of distinct types of endometriotic lesion (such as peritoneal,
ovarian and rectovaginal) (Nisolle and Donnez, 1997). In addition, it
may also be difﬁcult to distinguish between cause and effect: differ-
ences in eutopic endometrium between patients with and without
endometriosis, or in eutopic versus ectopic endometrium, may be
the cause of this pathological condition or the result of another
causative factor.
Although endometriosis can be treated surgically, recurrence of
endometriotic lesions can occur. GnRH agonists and long-cycle oral
contraceptives can also be used to manage the condition by suppres-
sing ovulation and inducing a pseudo-menopausal state. Although
many potential new agents, such as aromatase inhibitors, progester-
one antagonists and immunomodulatory drugs, have been investi-
gated, there is still a lack of suitable alternative pharmacological
treatments (Guo, 2008; Huang, 2008; Vercellini et al., 2009). A
better understanding of the pathogenesis of endometriosis may help
to identify new pharmacological targets and facilitate the development
of new treatments.
Genetics of endometriosis
It has been proposed that endometriosis results from a series of mul-
tiple hits within target genes, in a mechanism similar to the develop-
ment of cancer (Bischoff and Simpson, 2004). The initial mutation
may be either somatic or heritable.
Endometriosis has long been recognized as having a familial associ-
ation; data are consistent with a complex genetic basis (Malinak et al.,
1980; Simpson et al., 1980). Gene expression microarray studies have
identiﬁed a number of candidate gene families that may be differentially
regulated in endometriosis (Kao et al., 2003; Wu et al., 2006; Burney
et al., 2007; Hull et al., 2008; Ohlsson Teague et al., 2009). A search
for genetic polymorphisms associated with susceptibility to endome-
triosis has focused mainly on genes involved in inﬂammation, steroid
hormone regulation, metabolism, biosynthesis, detoxiﬁcation, vascular
function and tissue remodelling (Tempfer et al., 2009). However,
some polymorphisms have been investigated in only a single or a
limited number of studies and, in some cases, conﬂicting results
have been obtained. The majority of polymorphisms studied have,
therefore, been found not to be associated with endometriosis. An
evaluation of SNPs in 22 miRNAs that were differentially expressed
in paired ectopic and eutopic endometria in women with endometrio-
sis, however, identiﬁed two SNPs that were signiﬁcantly associated
with endometriosis-related infertility and disease severity: Wolf–
Hirschhorn syndrome candidate gene 1 (WHSC1) alleles and solute
carrier family 22, member 23 (SLC22A23) haplotypes (Zhao
et al., 2011).
Two studies have shown differential expression of miRNAs in
microarray analysis of eutopic and ectopic endometrial tissues (Pan
et al., 2007; Ohlsson Teague et al., 2009). Although eight miRNAs
were differentially expressed in both studies, the direction of dysregu-
lation was not in agreement for any of these (Ohlsson Teague et al.,
2010). A recent study using next-generation sequencing reported 22
dysregulated miRNAs (10 up-regulated miRNAs and 12 down-
regulated miRNAs) in endometriomas compared with eutopic endo-
metrium; miR-29c was implicated as a key up-regulated miRNA in
endometriosis (Hawkins et al., 2011b). It is likely that speciﬁc
miRNAs have a function in the pathophysiology of endometriosis,
and the differences in results could be due to many factors, including
the menstrual cycle phase at the time of biopsy. The putative roles of
miRNAs in endometriosis and other reproductive diseases are
described extensively in a recent review (Hawkins et al., 2011a).
A recent GWAS has identiﬁed a strong association signal for endo-
metriosis at locus 7p152 (Painter et al., 2011). This locus is located in
an intergenic region upstream of two plausible candidate genes,
NFE2L3 and HOXA10.
Epigenetic factors
Single molecular alterations in endometriosis may result in differential
regulation of hormone metabolism (Attar and Bulun, 2006). The
alterations may arise through epigenetic mechanisms such as DNA
methylation. An example is transcriptional activation of SF-1
(NR5A1) in endometriotic stromal cells by hypomethylation of DNA
(Xue et al., 2007). The presence of SF-1 in endometriosis and its
absence in the endometrium are determined primarily by the methyl-
ation of its promoter. In endometriotic lesions, the presence of SF-1
may contribute to increased oestrogen production (Bulun et al., 2009).
Stem cells: a new perspective
Stem cells located in the basal layer of the endometrium are thought
to be responsible for cyclical tissue regeneration. Studies have been
performed to isolate and characterize this cell population (Kato
et al., 2007, 2010; Cervello´ et al., 2010; Gargett and Masuda, 2010;
Masuda et al., 2010). Such studies have identiﬁed a population of can-
didate endometrial stem cells in human endometrium; the cells
Figure 3 A theoretical model of the development of
endometriosis.
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demonstrate multipotency and are different from other endometrial
cell types. These cells have been termed side population cells (SP
cells) as they exhibit a side population phenotype upon staining with
Hoechst dye and ﬂow cytometric analysis. SP cells have been demon-
strated to proliferate and differentiate into various endometrial cell
types in vitro and have unique angiogenic and migratory properties
(Masuda et al., 2010). Functional proof-of-concept studies have
shown that human endometrium can be reconstructed in immuno-
deﬁcient mice upon injection with human endometrial SP cells
(Cervello´ et al., 2010).
It has been suggested that the retrograde menstruation of SP cells
and subsequent implantation onto the surface of ectopic sites are
responsible for the establishment of endometriotic lesions (Sasson
and Taylor, 2008; Masuda et al., 2010). It has also been hypothesized
that an initial genetic mutation may cause aberrant behaviour of a sub-
population of endometrial stem cells; clonal expansion of such cells
may then occur and result in development of endometriosis
(Gargett et al., 2009). It is also conceivable that peritoneal cells
could undergo de-differentiation back to endometrial cells, which
take on an altered activity (Gargett et al., 2009).
Studies of endometrial stem cells have provided a new focus for
endometriosis research. Research on this subpopulation of endo-
metrial cells could be of particular value; the ﬁndings may further
our understanding of the pathogenesis of endometriosis and provide
new therapeutic approaches.
Predictors of oocyte quality and
successful embryo development
Currently, many couples with fertility problems resort to IVF or ICSI
when other treatments fail. Problems related to multiple pregnancies
and poor embryo implantation are among the factors that may limit
the success of IVF. The improvement of in vitro techniques, with
sequential or co-culture systems, and subsequent reduction in the
number of embryos transferred per cycle have ameliorated problems
related to multiple pregnancy. However, implantation rates in IVF have
not improved in the last decade (Nygren et al., 2006; Andersen et al.,
2008). Any objective procedure that could assess the oocyte compe-
tence and potential for embryo implantation and development should
increase success rates in assisted reproductive technology (ART).
In the study of oocyte competence, in recent years, the cumulus cell
complex that surrounds and connects with the oocyte has received
renewed attention. In a mouse model, this complex has been
shown to play a central role in ovulation, and the capacity of the
oocytes to support cumulus gene expression has been shown to be
linked to the oocyte’s developmental competence (Russell and
Robker, 2007). Cumulus gene expression proﬁling therefore rep-
resents a possible means of identifying reliable biomarkers for
oocyte quality and competence. It may also be useful to identify
biomarkers for embryo development prediction.
Cumulus gene expression proﬁling
Many studies suggest that cumulus cells: (i) coordinate follicular devel-
opment with oocyte maturation, (ii) provide energy substrates for
oocyte meiotic resumption, (iii) regulate oocyte transcription, (iv)
promote nuclear and oocyte molecular maturation, (v) stimulate
amino acid transport and sterol biosynthesis, (vi) promote glycolysis
and (vii) provide protection for the oocyte (Sugawara et al., 1997;
Elvin et al., 1999b, 2000; Varani et al., 2002; Sutton et al., 2003;
Pangas et al., 2004; Su et al., 2004; Eppig et al., 2005; Diaz et al.,
2007; Gilchrist et al., 2008). The vital supporting role of cumulus
cells during in vivo and in vitro maturation has led many groups recently
to focus research interest on cumulus cells. Isolated cumulus cells are
relatively homogeneous with almost no contamination with other
cells, whereas isolated granulosa cells, despite meticulous efforts, gen-
erally contain theca and blood cells: this is due to the methods
employed for obtaining these cells. In addition, with the advent of
the functional genomics and proteomics era, it has become possible
to identify the transcriptome and proteome of cumulus cells using
high-throughput technologies, such as microarray (Assou et al.,
2006) and high-resolution two-dimensional protein electrophoresis
(Hamamah et al., 2006). The current concept is that cumulus cells
may constitute a reliable model for understanding oocyte quality
and ovarian hyperstimulation protocol efﬁciency and may indirectly
predict oocyte aneuploidy, embryo development and pregnancy out-
comes (McKenzie et al., 2004; Zhang et al., 2005; Feuerstein et al.,
2007; van Montfoort et al., 2008).
Cumulus cells as biomarkers to assess oocyte quality, embryo
competence and pregnancy outcome
Cumulus cells are typically discarded during classical IVF and ICSI.
These cells are easily accessible and plentiful, which makes them an
ideal material to use for the assessment of oocyte quality and
embryo development potential. Thus, analysis of gene expression in
cumulus cells may provide an indirect indication of the microenviron-
ment in which the oocyte matures, and will help embryologists to
better assess embryo quality. Currently, the most common ways of
evaluating embryo quality non-invasively are by examining parameters
such as morphology and cleavage rate. However, these approaches
are subjective and lack precision. Several groups have used microarray
technologies, reverse transcriptase PCR (RT–PCR) and quantitative
RT–PCR analyses to study the association between cumulus cell
gene expression proﬁles and oocyte competence, embryo quality
and pregnancy outcome (Table III) (McKenzie et al., 2004; Cillo
et al., 2007; Feuerstein et al., 2007; Assou et al., 2008, 2010; van
Montfoort et al., 2008; Anderson et al., 2009; Hamel et al., 2010;
Wathlet et al., 2011). In a new and indirect approach for predicting
embryo quality and pregnancy outcome, gene expression signatures
have been identiﬁed recently by Assou et al. (2008, 2010) using tran-
scriptomic data of cumulus cells. This non-invasive approach is based
on the level of expression of potential biomarkers in cumulus cells
(indicators of successful pregnancy) to assess the potential and
quality of the embryo.
Cumulus cell gene expression analysis for optimization of ovarian
hyperstimulation protocols
As cumulus cells respond to stimulation protocols with a distinct gene
expression proﬁle and are sensitive to changes in environmental con-
ditions, it may be possible to identify the genes that are expressed in
the follicular environment. The individual characterization of gene
expression may provide important insights for the evaluation of the
impact of ovarian hyperstimulation protocols used during IVF.
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Using fertilized and non-fertilized oocytes resulting from speciﬁc
ovarian hyperstimulation protocols, potential differences in the
protein expression proﬁles of cumulus cells have been investigated
(Hamamah et al., 2006). In cumulus cells from either fertilized or non-
fertilized oocytes, the greatest degree of similarity (more than 85%)
was in the protein expression proﬁles. The analysis of protein
expression proﬁles of cumulus cells from follicles obtained with the
same ovarian hyperstimulation protocol showed a strong correlation
between protein expression proﬁles whether or not embryos had
been produced successfully. More than 80% of proteins were
expressed similarly between cumulus cells from fertilized versus unfer-
tilized oocytes from a cycle in a single patient that used a long GnRH
protocol with human menopausal gonadotrophin (HP-hMG). In con-
trast, when cumulus cell protein expression proﬁles were analysed
in oocytes with the same outcome from the same patient, but orig-
inating from different ovarian hyperstimulation protocols, a signiﬁcant
difference was seen in the protein expression proﬁles. Comparing
protein expression proﬁles in cumulus cells from fertilized oocytes
from the same patient, but after GnRH agonist long protocols with
HP-hMG compared with those with recombinant FSH, only 55% of
the proteins showed similar mobility and expression levels. Compari-
son of two groups of patients indicated that dissimilarities in protein
pattern between patients become very high, even when comparing
the same stimulation protocol and oocyte fertilization outcome.
These data from protein expression proﬁling of human cumulus cells
suggest that there may be a correlation between the synthesis of
speciﬁc cumulus cell proteins and the maturity and fecundity of the
oocyte. The study reveals three important new ﬁndings with respect
to human cumulus cell biology: (i) human cumulus cells have robust
metabolic activity, (ii) the overall protein expression proﬁles are
highly similar between cumulus cells from oocytes obtained using
the same ovarian hyperstimulation protocol and (iii) there are signiﬁ-
cant differences in protein expression between cumulus cells from
oocytes obtained under two different ovarian hyperstimulation
protocols, even when the outcomes are the same (Hamamah et al.,
2006).
Cumulus cell gene expression analysis in PCOS and aneuploidy
identiﬁcation
Cumulus cells play a major role in the control of oocyte metabolism
and, therefore, it is likely that malfunction of these cells might play a
role in PCOS. Recently, the gene expression proﬁle of cumulus cells
isolated from patients with PCOS has been studied (Kenigsberg
et al., 2009). The different gene expression patterns of cumulus cells
from lean and obese women with PCOS support the idea that in
the two types of patient, the condition may have different pathophy-
siologies. Furthermore, in recent years, several groups have initiated
research aimed at identifying non-invasive biomarkers of chromosome
imbalance. Some investigators have detected characteristic transcrip-
tional changes in the cumulus cells attached to aneuploid oocytes
(Wells et al., 2008). This suggests that genes involved in the meiotic
process in human oocytes are regulated by genes expressed in
cumulus cells.
‘Omics’ technologies for embryo assessment
Accurate selection of the most appropriate embryo for SET has been
a major aim for reproductive specialists in recent years. To date, the
.............................................................................................................................................................................................
Table III Association of cumulus cell gene expression with embryo quality and pregnancy outcomes.
Cumulus cell origin Approaches Biomarkers Outcome Reference
Individual oocytes Microarray (50
chips)
Including PCK1, BCL2L11, NFIB and others Predict embryo and pregnancy
outcomes
Assou et al. (2008)
Individual oocytes Microarray (16
chips)
CCND2, CXCR4, GPX3, HSPB1, DVL3,
DHCR7, CTNND1, TRIM28
Negatively associated with oocyte
competence
van Montfoort
et al. (2008)
Individual oocytes RT–PCR HAS2, GREM1 Positively associated with oocyte
developmental competence
Cillo et al. (2007)
Individual oocytes RT–PCR STAR, AREG, CX43, PTGS2, SCD1, SCD5 Negatively associated with oocyte
competence
Feuerstein et al.
(2007)
Individual oocytes qRT–PCR HAS2, PTGS2, GREM1 Positively associated with oocyte
competence and embryo development
McKenzie et al.
(2004)
Individual oocytes qRT–PCR GREM1, BDNF Positive and negative predictors of
embryo quality, respectively
Anderson et al.,
(2009)
Mural granulosa cells
and individual oocytes
qRT–PCR PGK1, RGS2, RGS3, CDC42 Associated with pregnancy Hamel et al. (2010)
Individual oocytes qRT–PCR SDC4, PTGS2, VCAN, activated leucocyte cell
adhesion molecule, GREM1, TRPM7, ITPKA
Predict embryo development and
pregnancy
Wathlet et al.
(2011)
Modiﬁed with permission from Assou et al. (2010). AREG, amphiregulin; BCL2L11, BCL-like protein 11; BDNF, brain-derived neurotrophic factor; CCND2, cyclin D2; CDC42, cell
division cycle 42; CTNND1, catenin delta 1; CX43, connexin 43; CXCR4, chemokines receptor 4; DHCR7, 7-dehydrocholesterol reductase; DVL3, dishevelled dsh homolog 3;
GPX3, glutathione peroxidase; GREM1, gremlin 1; HAS2, hyaluronic acid synthase 2; HSPB1, heatshock 27 kDa protein 1; ITPKA, inositol 1,4,5-trisphosphate 3-kinase A; NFIB,
nuclear factor 1B; PCK1, phosphoenolpyruvate carboxykinase 1; PGK1, phosphoglycerate kinase 1; PTGS2, prostaglandin-endoperoxide synthase 2; qRT–PCR, quantitative real-time
PCR; RGS2, regulator of G-protein signalling 2; RGS3, regulator of G-protein signalling 3; RT–PCR, real-time PCR; SCD1, stearoyl-co-enzyme A desaturase 1; SCD5,
stearoyl-co-enzyme A desaturase; SDC4. syndecan 4; STAR, steroidogenic acute regulatory protein; TRIM28, tripartite motif-containing 28; TRPM7, transient receptor potential cation
channel, subfamily M, member 7; VCAN, versican.
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only universally used method to score the potential development and
implantation capability of the human embryo is morphological assess-
ment. Therefore, there is a need for new adjunctive technologies for
determining the best embryo for transfer and improvement of implan-
tation rates. Successful embryo implantation requires endometrial
receptivity, the development of a viable embryo and adequate
bi-directional communication between the blastocyst and endome-
trium. The advent of the era of high-throughput ‘omic’ methodologies
(genomics, transcriptomics, proteomics and metabolomics) has facili-
tated the study of such processes.
Some of these technologies may provide non-invasive methods for
embryo evaluation in the future.
Genomics
Preimplantation genetic screening (PGS) can be used during early
stages of embryo development to assess aneuploidy. In some
countries, PGS is used to maximize the chances of a successful preg-
nancy in certain patient subpopulations, such as those of advanced
maternal age, or women with a history of recurrent implantation
failure or miscarriage.
However, the use of PGS is associated with a number of potential
drawbacks. Standard PGS methods utilize a Day-3 biopsy, in which
one or two blastomeres are removed from the embryo, followed by
FISH to detect chromosomal abnormalities. Therefore, the loss of
embryos and a reduction in embryo quality are possible. Furthermore,
there is a high rate of mosaicism in Day-3 embryos (which might lead
to an incorrect diagnosis), and the survival of embryos after blasto-
mere removal and subsequent cryopreservation has been found to
be severely reduced (Joris et al., 1999; Platteau et al., 2006).
Several comprehensive chromosome analysis methods are now
available, including aCGH, quantitative PCR and SNP microarrays
(Johnson et al., 2010). aCGH evaluates aneuploidy of each pair of
chromosomes and results can be available within 24 h. Combined
with single blastomere biopsy on Day-3 embryos, aCGH has been
shown to be robust, with only 2.9% of embryos with no results,
and associated with low error rates (1.9%) (Gutie´rrez-Mateo et al.,
2011). Unlike SNP arrays, aCGH does not require prior testing of par-
ental DNA; therefore, advanced planning and careful scheduling are
unnecessary. A short CGH method has also been shown to detect
more chromosomal aneuplodies than FISH and has been used suc-
cessfully to achieve pregnancy (Rius et al., 2011).
Transcriptomics
Over the last decade, microarray studies have characterized the gene
expression proﬁle of the human endometrium in different physiological
states, such as during decidualization, the window of implantation,
endometriosis, the normal menstrual and stimulated cycles, and endo-
metrial cancer (Horcajadas et al., 2007; Haouzi et al., 2009a, b).
However, gene expression proﬁling studies of human embryos are
limited, due to legal and ethical issues. Data on early mammalian
development have been provided mainly by murine studies (Tanaka
et al., 2000; Hamatani et al., 2004; Wang et al., 2004; Jeong et al.,
2006).
Gene expression proﬁle studies in cumulus and granulosa cells have
been described earlier and are summarized in Table III. Such studies
have identiﬁed candidate biomarkers for oocyte quality and compe-
tence (Cillo et al., 2007; Hamel et al., 2008), early embryo
development (McKenzie et al., 2004; van Montfoort et al., 2008;
Anderson et al., 2009) and embryo quality and pregnancy outcome
(Assou et al., 2008; Hamel et al., 2010). Furthermore, in mice, blasto-
cyst gene expression proﬁles correlate with outcome, including suc-
cessful implantation and pregnancy loss (Parks et al., 2011). miRNA
expression in human blastocysts is different in transferable blastocysts
from infertile patients (male factor infertility and those from women
with PCOS) compared with those from donor fertile controls, and
it has been suggested that an association of aberrant miRNA proﬁles
may exist with human infertility (McCallie et al., 2010).
Transcriptomic studies may provide valuable information that could
lead to the identiﬁcation of biomarkers. For a comprehensive review,
refer to Assou et al. (2011).
Proteomics
Although not as developed as the genomics/transcriptomics method-
ologies, proteomic analysis of mammalian embryos is also emerging as
a powerful assessment tool (Katz-Jaffe et al., 2005; Shankar et al.,
2005). Analysis of the proteome of individual human embryos has
the potential to provide novel biomarkers of good embryo develop-
ment and implantation potential (Katz-Jaffe et al., 2006a). Further-
more, by using bioinformatics to create networks linking proteins
found to be differentially regulated between biological samples, func-
tional pathways can be identiﬁed (Dominguez et al., 2010).
However, analysis of the proteome in a research setting requires
extraction of proteins from lysed blastocysts, which limits the use of
this technology in routine embryo assessment.
Analysis of the proteins contained in the surrounding embryo
culture medium may provide a non-invasive method of using proteo-
mic techniques to identify novel biomarkers of embryo viability (Katz-
Jaffe et al., 2006b). Domı´nguez et al. have used protein array analysis
to characterize pooled spent sequential culture media prior to SET
and to compare it with control media. A lower abundance of
CXCL13, stem cell factor and macrophage-stimulating protein–a,
but a higher abundance of soluble TNF receptor 1 was detected in
the sequential culture media containing a blastocyst relative to the
control (Domı´nguez et al., 2008). Furthermore, blastocysts that
went on to successfully implant were found to have a relatively
lower abundance of CXCL13 and granulocyte-macrophage
colony-stimulating factor in their culture media than those that did
not implant; these proteins may be markers of successful implantation
ability (Domı´nguez et al., 2008).
Domı´nguez et al. have also used co-culture studies to explore the
role of the endometrium in implantation. This technique involves
endometrial biopsy, followed by separation and culture of the endo-
metrial epithelial cells (EEC). A total of 32 proteins were found to
be up- or down-regulated in blastocysts that went on to successfully
implant and were co-cultured with EEC relative to those cultured in
sequential media; of these proteins, interleukin 6 (IL-6) was found
to be the most abundantly secreted in the EEC culture. Furthermore,
the IL-6 concentration in sequential media from blastocysts that
implanted was signiﬁcantly lower than that of blastocysts that did
not implant (Dominguez et al., 2010). The proteomics of endometrial
receptivity have also been studied by analysis of endometrial biopsies
taken during the pre-receptive and receptive phases of the menstrual
cycle (DeSouza et al., 2005; Domı´nguez et al., 2009; Haouzi et al.,
2009a, b). Two proteins found to be differentially expressed in pre-
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receptive and receptive endometria were stathmin 1 and annexin A2
(down- and up-regulated in the receptive endometrium, respectively)
(Domı´nguez et al., 2009). Support for the involvement of these pro-
teins in endometrial receptivity was provided by the pre-receptive
pattern of stathmin 1 and annexin A2 expression observed when an
intrauterine device was used to model the non-receptive endome-
trium (Domı´nguez et al., 2009). In previous studies, a quantitative
approach for proteomic assessment using isotope-coded afﬁnity
tags, afﬁnity puriﬁcation and online tandem mass spectrometry has
been used to study differences between proliferative and secretory
endometria (DeSouza et al., 2005). Only ﬁve proteins with signiﬁcant
differential expression were found; the glutamate NMDA receptor
subunit zeta 1 precursor and FRAT1 were of greatest interest.
Endometrial receptivity has also been studied by other groups using
non-invasive techniques. Boomsma et al. (2009) have used a multiplex
immunoassay to analyse endometrial secretions, aspirated immedi-
ately prior to embryo transfer during IVF. Using this approach, cyto-
kine proﬁles predictive of implantation and clinical pregnancy have
been identiﬁed (Boomsma et al., 2009). The data obtained provide
support for associations between MCP-I and IP-10 levels with implan-
tation, and IL-1b and TNF-a levels with clinical pregnancy (Boomsma
et al., 2009).
Recent studies have investigated discriminating signatures between
individual euploid and aneuploid blastocysts. Microdrops of spent
IVF culture medium from individual blastocysts of transferable quality
were processed and analysed by surface-enhanced laser desorption/
ionization time-of-ﬂight mass spectrometry to determine a blastocyst
secretome ﬁngerprint. Each individual blastocyst was then subjected
to CGH for comprehensive analysis of all chromosomes (Fragouli
et al., 2008). Of the 14 aneuploid blastocysts analysed, nine had a
single chromosomal aneuploidy and ﬁve had chaotic changes involving
more than two chromosomes. Secretome ﬁngerprints from individual
blastocysts identiﬁed protein signatures that allowed discrimination
between euploid and aneuploid chromosomal constitutions (Katz-Jaffe
et al., 2008).
Metabolomics
Metabolites represent the end products of cell regulatory processes
and can be used to study the response of biological systems to
genetic, nutritional and environmental inﬂuences; the metabolome
(i.e. the complete set of small molecule metabolites found within a
biological sample) therefore provides a good indicator of cellular
activities.
High-resolution nuclear magnetic resonance (NMR) has been used
to analyse the metabolic proﬁle of follicular ﬂuid samples from oocyte
donors and has identiﬁed metabolites that could be useful as bio-
markers of the follicular maturation state (Pinero-Sagredo et al.,
2010). NMR spectroscopy has also been used for compositional analy-
sis of other areas of the reproductive tract, including cervical mucus,
ovarian tissue, fallopian tubes and uterine matter (Baskind et al.,
2011). Incorporation of such techniques into female fertility research
may be valuable for understanding subfertility and for predicting out-
comes of assisted conception treatments (Baskind et al., 2011).
Metabolomic technology is being used in the development of a new
method for aneuploidy detection. This approach is based on the
assumption that an embryo with a missing or extra chromosome
may have modiﬁed metabolism. Given the drawbacks of the use of
PGS to detect chromosomal abnormalities, alternative methods
would be of value. Analysis of the global metabolome of the
embryo (using a combination of ultra-performance liquid chromato-
graphy and mass spectroscopy) to analyse low-molecular-weight mol-
ecules in spent culture media allows study of the embryo without
invasive techniques (unlike PGS). By correlating metabolomic proﬁles
with the results of subsequently performed PGS, it has been possible
to differentiate between embryos with normal and abnormal chromo-
some numbers, and even classify embryos according to their chromo-
somal anomaly (Sanchez-Ribas et al., 2008). Although this technique
may be limited by the low quantity of metabolites in spent culture
media, preliminary results are promising and encourage further devel-
opment of this non-invasive tool for embryo assessment.
Aneuploidy screening represents a unique and valuable application
of metabolomics. Analysis of the metabolomic proﬁle of embryo
culture media using infra-red techniques is also being explored as an
embryo assessment strategy (Seli et al., 2007, 2010; Scott et al., 2008).
Translating ‘omics’ technologies to the ART clinic
As with any ART procedure, the easier the technique, the more likely
that it can be used to produce reliable results in routine procedures in
ART clinics. Most ART laboratories have, or have easy access to,
enzyme-linked immunosorbent assay platforms for routine hormone
testing. However, few laboratories have sophisticated equipment for
performing quantitative PCR or mass spectrometry. If the cost of
this equipment falls over time, or as more focused assays become
available, one or more of these technologies may become used routi-
nely in clinical practice. Another possibility is that as procedures
become routine and as key genes, proteins or small molecules are
identiﬁed that correlate with pregnancy outcomes, clinical samples
(cumulus cells, media from embryo cultures or blastomeres) could
be collected and stored in specialized solutions or containers, and
testing could be performed at a commercial facility. Such a process
could allow cost-effective performance of the assays and standardiz-
ation of the technologies. In addition, this practice could allow selec-
tion of high-quality oocytes based on cumulus cell proﬁles after the
oocytes have been vitriﬁed. Under such circumstances, there would
not be immediate time pressures to obtain the results and oocytes
could be assessed before transfer in a subsequent cycle. In the
future, it is likely that a combination of multiple technologies will be
used with the goal of obtaining a healthy newborn on the ﬁrst
attempted embryo transfer.
Conclusions
In conclusion, our knowledge of ovarian genetics is rapidly expanding
and this review provides an important update of those genes identiﬁed
to have a role in infertility, particularly POI. To date, the search for a
candidate gene for PCOS has produced limited positive ﬁndings
despite involvement of numerous genes. In the ﬁeld of endometriosis,
it has been proposed that the condition results from a series of mul-
tiple hits within target genes and gene expression microarray studies
have identiﬁed a number of candidate gene families that may be differ-
entially regulated. The members of the Fifth EVAR Workshop Group
agreed that the way forward in advancing the knowledge of genes
involved in reproduction and fertility-associated pathologies was
through GWAS involving large numbers of patients. As GWAS are
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expensive to conduct, it was suggested that pooling of data from
different research groups may be the way forward.
Future challenges for genomics and genetic screening of patients
include identiﬁcation of high-throughput strategies and how to apply
ﬁndings to patients being seen in the ART clinic. The identiﬁcation
of high-quality embryos in ART remains a priority in order to select
those with high potential development and implantation capability
for transfer. Gene expression proﬁling of cumulus cells and proteomic
and metabolomic technologies show promise for non-invasive oocyte
and embryo assessment.
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